-
Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor : data from the BioRx.si registryRotar, Žiga ...This study aimed to investigate the retention of the second-line biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis patients failing their first tumor necrosis factor ... alpha inhibitor (TNFi). Data was extracted from the Slovenian registry (BioRx.si) on December 15, 2012. Baseline patient characteristics were compared between second-line TNFi and non-TNFi, and potential confounders were identified by the means of binary logistic regression. Differential drug retention was assessed using the Kaplan-Meier method and crude and inverse probability-weighted Cox proportional hazards regression models (Cox model). Two hundred thirty-eight out of 688 patients who received a TNFi as the first biologic were switched to another biologic: 130 to a second-line TNFi and 108 to either rituximab (31.5 %) or tocilizumab (68.5 %) (non-TNFi). Disease activity at starting second-line bDMARD and stopping the first-line TNFi due to either lack of effectiveness or loss of effectiveness were identified as potential confounders. There appears to be a statistically significant retention advantage of the non-TNFi over the second-line TNFi (log rank test, p%=%0.000). This advantage is retained even after taking into account the possible effect of confounders which was tested using the inverse probability-weighted Cox model [hazard ratio (HR) 4.39; 95 % confidence interval (CI) 2.62%8.01, p%<%0.001]. After the first-line TNFi's failure, a second-line TNFi is more likely to fail earlier than non-TNFi.Vir: Clinical rheumatology. - ISSN 0770-3198 (Vol. 34, no. 10, Oct. 2015, str. 1787-1793)Vrsta gradiva - članek, sestavni del ; neleposlovje za odrasleLeto - 2015Jezik - angleškiCOBISS.SI-ID - 32177625
Avtor
Rotar, Žiga |
Hočevar, Alojzija |
Rebolj, Anamarija, 1985- |
Praprotnik, Sonja |
Tomšič, Matija, 1959-
Drugi avtorji
Holc, Iztok, 1963- |
Koren Krajnc, Metka |
Kovačič Grobelšek, Vesna |
Lestan, Boris |
Logar, Dušan, 1951- |
Pahor, Artur |
Petric, Vlasta |
Perdan-Pirkmajer, Katja |
Plešivčnik-Novljan, Martina |
Sinožić, Dean |
Šipek-Dolničar, Alenka |
Žužek, Tanja, 1964-
Teme
rheumatoid arthritis |
rituximab |
tocilizumab |
revmatoidni artritis |
tocilizumab |
rituximab
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Rotar, Žiga | 30545 |
Hočevar, Alojzija | 22344 |
Rebolj, Anamarija, 1985- | 32048 |
Praprotnik, Sonja | 13602 |
Tomšič, Matija, 1959- | 13601 |
Holc, Iztok, 1963- | 23194 |
Koren Krajnc, Metka | 38451 |
Kovačič Grobelšek, Vesna | |
Lestan, Boris | 02087 |
Logar, Dušan, 1951- | 10080 |
Pahor, Artur | 15750 |
Petric, Vlasta | 32461 |
Perdan-Pirkmajer, Katja | 29467 |
Plešivčnik-Novljan, Martina | 16184 |
Sinožić, Dean | |
Šipek-Dolničar, Alenka | 10645 |
Žužek, Tanja, 1964- |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.